Junling Zhuang

1.1k total citations
87 papers, 665 citations indexed

About

Junling Zhuang is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Junling Zhuang has authored 87 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 32 papers in Oncology and 30 papers in Molecular Biology. Recurrent topics in Junling Zhuang's work include Multiple Myeloma Research and Treatments (33 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (9 papers). Junling Zhuang is often cited by papers focused on Multiple Myeloma Research and Treatments (33 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (9 papers). Junling Zhuang collaborates with scholars based in China, United States and India. Junling Zhuang's co-authors include Claire M. Edwards, Gregory R. Mundy, Seint T. Lwin, Daobin Zhou, James Edwards, Xiangli Yang, Jianghong Zhang, Bing Han, Miao Chen and Jianhua Du and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Junling Zhuang

70 papers receiving 659 citations

Peers

Junling Zhuang

HEMAT

ONCOL

IMMUN

GENET

Yasutaka Hoshi Japan

Akihito Fujimi Japan

Hana Safah United States

Pierre Hirsch France

Mike Keeney Canada

Shingo Wakatsuki Japan

Hidemitsu Kurosawa Japan

Qin Huang United States

Chikako Ohwada Japan

Mineo Kurokawa Japan

Yasutaka Hoshi Japan

Junling Zhuang

389 ×1.3

HEMAT

233 ×0.9

ONCOL

291 ×1.3

140 ×1.1

IMMUN

111 ×1.4

GENET

Citations per year, relative to Junling Zhuang Junling Zhuang (= 1×) peers Yasutaka Hoshi

Countries citing papers authored by Junling Zhuang

Since Specialization

Citations

This map shows the geographic impact of Junling Zhuang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junling Zhuang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junling Zhuang more than expected).

Fields of papers citing papers by Junling Zhuang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junling Zhuang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junling Zhuang. The network helps show where Junling Zhuang may publish in the future.

Co-authorship network of co-authors of Junling Zhuang

This figure shows the co-authorship network connecting the top 25 collaborators of Junling Zhuang. A scholar is included among the top collaborators of Junling Zhuang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junling Zhuang. Junling Zhuang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Lie, Junling Zhuang, & Mo Wang. (2025). Integrating AHP-SBE for Evaluating Visitor Satisfaction in Traditional Village Tourism Landscapes. Sustainability. 17(7). 3119–3119. 3 indexed citations

Yang, Chen, et al.. (2025). Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study. Annals of Medicine. 57(1). 2514791–2514791. 1 indexed citations

Yang, Mingshi, Junling Zhuang, & Mo Wang. (2025). Leveraging Recurrent Neural Networks for Lithology Identification and Chinese Rural Landscape Planning in Sustainable Design. Sustainability. 17(7). 3078–3078.

Li, Hui, et al.. (2024). Myc rearrangement redefines the stratification of high‐risk multiple myeloma. Cancer Medicine. 13(11). e7194–e7194. 3 indexed citations

Li, Ziping, et al.. (2024). Identifying immune checkpoints on dysregulated T-cells as prognostic biomarkers for multiple myeloma patients with COVID-19. Frontiers in Immunology. 15. 1448653–1448653.

Wang, Mo, et al.. (2024). The Application of Rain Gardens in Urban Environments: A Bibliometric Review. Land. 13(10). 1702–1702. 8 indexed citations

Li, Ziping, et al.. (2024). Impaired acute‐phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS ‐ CoV ‐2 Omicron variants outbreak infection. International Journal of Cancer. 155(8). 1500–1509. 1 indexed citations

Jin, Song, Junling Zhuang, Xin Zhou, et al.. (2024). Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study. Blood. 144(Supplement 1). 6970–6970.

Liu, Shuzhong, et al.. (2024). Percutaneous vertebroplasty/kyphoplasty contributes to the improved outcome in patients with newly diagnosed multiple myeloma: A single center cohort study. Journal of bone oncology. 47. 100615–100615.

10.

Ruan, Min, Xinyao Liu, Wei Wu, et al.. (2023). Efficacy and Safety of Low-Dose Venetoclax Combined with Voriconazole Inpatients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy. Blood. 142(Supplement 1). 5968–5968.

11.

Zhuang, Junling, et al.. (2023). Adding Hetrombopag to Cyclosporine a to Patients with Newly Diagnosed Transfusion-Dependent Non-Severe Aplastic Anemia-a Prospective Phase 2 Study. Blood. 142(Supplement 1). 5005–5005.

12.

Liu, Aijun, Wen-Ming Chen, Yin Wu, et al.. (2023). P959: MAINTENANCE THERAPY FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANTATION BY IXAZOMIB AND/OR LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTICENTERED REAL WORLD STUDY IN CHINA. HemaSphere. 7(S3). e3162941–e3162941. 1 indexed citations

13.

Zhuang, Junling, Jianhua Du, Xiaoxiao Guo, et al.. (2020). Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events. Thoracic Cancer. 11(3). 799–804. 29 indexed citations

14.

Feng, Jun, Xinxin Cao, Jian Li, et al.. (2019). Efficacy observation of lenalidomide and rituximab in treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. 28(6). 321–326.

15.

Chen, Miao, et al.. (2018). Comparative study of porcine anti-human lymphocyte immunoglobulin and rabbit anti-human thymocyte immunoglobulin as a first-line treatment of acquired severe aplastic anemia. Leukemia Research. 65. 55–60. 16 indexed citations

16.

Zhu, Tienan, Shujie Wang, Wei Zhang, et al.. (2015). [Clinical characteristics and outcome of patients with primary central nervous system lymphoma].. PubMed. 36(10). 849–52. 3 indexed citations

17.

Wang, Yini, Rui Zhang, Huyong Zheng, et al.. (2015). [A multicenter retrospective etiological analysis of 601 patients with hemophagocytic lymphohistiocytosis in China].. PubMed. 54(12). 1018–22. 6 indexed citations

18.

Zhuang, Junling, Jianghong Zhang, Seint T. Lwin, et al.. (2012). Osteoclasts in Multiple Myeloma Are Derived from Gr-1+CD11b+Myeloid-Derived Suppressor Cells. PLoS ONE. 7(11). e48871–e48871. 98 indexed citations

19.

Zhuang, Junling, et al.. (2008). Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.. Journal of Bone and Mineral Research. 23. 1 indexed citations

20.

Zhuang, Junling, Lingling Yang, Edwards, Claire M. Edwards, & G R Mundy. (2007). Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche. Journal of Bone and Mineral Research. 22. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact